A Look at Some of the CLSI Recommendations for Antimicrobial Susceptibility Testing and Reporting(by CACMLE) (Online Course)

Janet Hindler, MCLS, MT(ASCP), F(AAM)

See all available courses »

Continuing Education Credits

Objectives

  • List some of the new recommendations for antimicrobial susceptibility testing and reporting published in the CLSI M100-S23.
  • Describe a strategy for dealing with some contemporary antimicrobial susceptibility testing challenges among gram-negative bacteria.
  • Discuss how to best report susceptibility test results for oxacillin, penicillin, and other beta-lactams that might be used for treating staphylococcal infections.

Course Outline

  • PowerPoint Slides
      • A Look at Some of the CLSI Recommendations for AST & Reporting
      • Learning Objectives
      • CLSI AST Standards
      • Summary of Changes
      • Case #1: Wound Drainage (Trauma)
      • Breakpoints Eliminated for Staphylococcus spp.
      • Staphylococcus spp. - Beta-Lactam Breakpoints Remaining
      • Staphylococcus spp. Penicillins & Penicillinases
      • Staphylococcus spp.- Beta-Lactams Use Pen and Ox results to predict other
      • Case #1: Wound Drainage - Final Report
      • Staphylococcus spp. - Beta-Lactams - Use Ox to predict results for other beta-lactams
      • Ceftaroline
      • Ceftaroline vs. Other Beta-Lactams - % Susceptible
      • Case #2: Wound (Severe Cellulitis)
      • Case #3: Stool (Diarrhea)
      • Salmonella spp. - AST & Reporting (1)
      • Case #3: Stool (Diarrhea) Final Report
      • Salmonella spp. - AST & Reporting (2)
      • Enterobacteriaceae
      • Case #4: Stool (Diarrhea)
      • Salmonella spp. % Susceptible - USA 2010
      • Case #5: Foot Ulcer
      • Group B Streptococcus (GBS)
      • Diabetic Foot - Infected Ulcer Etiologies
      • UCLA GBS (Jan 2011 - Feb 2013)
      • UCLA GBS and AST (Jan 2011 - Feb 2013)
      • Streptococcus spp. - Beta Hemolytic Group CLSI M 100-S23. Table 1B
      • Streptococcus spp. : Beta-Hemolytic Group - Penicillin
      • Group B Streptococcus - Intrapartum prophylaxis
      • Beta-Hemolytic Streptococci - Testing for Inducible Clindamycin Resistance
      • Case #5: Foot Ulcer Final Report
      • GBS: % Susceptible
      • Beta-hemolytic Streptococcus spp.: Penicillin MIC Distribution
      • GBS: Penicillin "Non-susceptible"
      • Case #5: Final Report
      • Inducible Clindamycin Resistance: Erythromycin- R, Clindamycin- S
      • Case #6: Final Report
      • Resources
      • Case #7: Pneumonia
      • Acinetobacter baumannii
      • Non-Enterobacteriaceae - M 100-S23. App. B2. Intrinsic Resistance
      • Case #7: Final Report
      • How can we define multi-drug resistance (MDR)?
      • Goal for establishing definitions
      • Definitions
      • CDC - Multi-drug Resistance in Healthcare Settings
      • MDR GNR Definition for Epidemiological Purposes
      • Case #8: Bacteremia - Final Report
      • Patients with A. baumannii infections and active drugs
      • Acinetobacter baumannii % Susceptible
      • Acinetobacter baumannii - Resistance Profiles
      • Summary (1)
      • Summary (2)
      • Summary (3)
      • Questions?



Slide 1


Slide 13


Slide 41